Compare / 2 molecules
Tesamorelin vs Sermorelin: A Structural and Pharmacologic Comparison
Both are GHRH analogues that work through the same receptor — but they differ in length, stability, and the depth of their evidence. A molecule-by-molecule comparison.
In plain English
Tesamorelin vs sermorelin is a comparison of two molecules that do the same basic job — telling the pituitary to release the body's own growth hormone — by copying the natural GHRH (the brain's "make growth hormone" signal). The difference is in the build. Sermorelin is a short fragment of GHRH; tesamorelin is the full-length version with a chemical cap added so it survives longer in the blood. They share a mechanism but not an evidence base: tesamorelin has been through large trials and an FDA review for one HIV indication, while sermorelin's research record is far thinner. This page compares the chemistry and what the evidence does and does not support.
Same Receptor, Different Molecules
Both tesamorelin and sermorelin are GHRH-receptor agonists: each binds the GHRH receptor on pituitary somatotrophs and stimulates pulsatile release of endogenous growth hormone, which raises IGF-1 [1]. Neither supplies growth hormone directly; both amplify the body's own GH rhythm. That shared mechanism is where the similarity ends.
Tesamorelin is a stabilized analogue of the complete, full-length human GHRH(1-44) sequence — all 44 amino acids — with a trans-3-hexenoic-acid group conjugated to its N-terminus [1]. Sermorelin is a truncated fragment: GHRH(1-29), the first 29 residues, which retains the biological activity of native GHRH but without tesamorelin's stabilizing modification. The length difference and the N-terminal cap are the two structural facts that separate them.
The DPP-IV Stability Difference
The decisive pharmacologic distinction is metabolic stability. Native GHRH — and unmodified GHRH fragments — are rapidly cleaved and inactivated by dipeptidyl peptidase-IV (DPP-IV) at the N-terminus. Tesamorelin's trans-3-hexenoic-acid N-terminal modification blocks that DPP-IV cleavage, extending its biological activity relative to native GHRH [1][7].
That engineered resistance is why tesamorelin's downstream IGF-1 elevation persists across a once-daily dosing interval despite the parent peptide's brief plasma half-life of roughly 26-38 minutes by secondary sources [1]. The takeaway is mechanistic, not a recommendation: the N-terminal cap is the feature that distinguishes tesamorelin from an unmodified GHRH analogue.
The Evidence Bases Are Not Equivalent
Where tesamorelin and sermorelin differ most for a reader weighing the literature is the depth of the human evidence. Tesamorelin carries an unusually mature record for this compound class: FDA approval in 2010 for HIV-associated lipodystrophy (NDA 022505), two pivotal Phase 3 RCTs, a JAMA hepatic-fat RCT, a 2024 integrase-inhibitor-era RCT, and a 2026 five-RCT meta-analysis pooling a VAT reduction of -27.71 cm2 [1][3][5][12][13].
This comparison does not recommend either molecule for any unapproved use. Tesamorelin's FDA approval is limited to HIV-associated lipodystrophy; every other use is off-label and investigational [5]. Sermorelin's own indications and evidence are outside the scope of this tesamorelin digest, which cites only the tesamorelin literature. The point of the contrast is structural and pharmacologic — full-length-and-stabilized versus truncated — not a head-to-head efficacy claim, which no trial in this record was designed to make.
How the Two Compare at a Glance
On structure: tesamorelin is the full-length GHRH(1-44) analogue (44 amino acids, 5135.9 Da) with a trans-3-hexenoyl N-terminal cap; sermorelin is the truncated GHRH(1-29) fragment without that modification [1]. On stability: tesamorelin resists DPP-IV cleavage; unmodified GHRH analogues do not [1][7]. On mechanism: identical — both are GHRH-receptor agonists that raise pulsatile GH and IGF-1 [1]. On evidence: tesamorelin has large RCTs, a meta-analysis, and a scoped FDA approval [5][12]; the comparison stops there, because making an efficacy ranking would require a head-to-head trial that does not exist in this record. For the receptor cascade in detail, see the mechanism of action module.